I was also pessimistic after listening in on the conference call this morning.
In regards to positive clinical data I personally think this is very likely given the Sirflox trial has already shown an increase in progression free survival in the liver of 7.9 months.
I would be very surprised if this doesn't result in a very good increase in overall survival and a move for Sirspheres into standard of care/first line treatment.
SRX Price at posting:
$16.00 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.